Investigation on antiviral agents against severe fever with thrombocytopenia syndrome virus (SFTSV)

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460559
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Virology
• Research Institution: Kagoshima University
• Principal Investigator: BABA MASANORI 鹿児島大学, 医歯学域医学系, 教授 (70181039)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 重症熱性血小板減少症候群 / SFTSV / 抗ウイルス薬 / アッセイシステム / アモジアキン

Outline of Final Research Achievements

SFTS is an emerging tick-borne infectious disease. Its fatality is quite high. However, there are no antiviral agents currently approved for clinical use. We have established a safe and rapid assay system for screening selective inhibitors of SFTSV and tested various compounds in the assay system. When ribavirin and favipiravir were examined for their anti-SFTSV activity, their EC50 values were 40.1 ± 16.3 and 25.0 ± 9.3 μM, respectively. Both compounds have already been reported as selective inhibitors of SFTSV replication in vitro. Furthermore, amodiaquine was found to be effective against SFTSV (EC50 = 19.1 ± 5.1 μM).

Free Research Field

ウイルス学